Skip to main content

Pfizer Inc Third-Quarter 2005 Performance Report

Pressmeddelande   •   Okt 20, 2005 14:49 CEST

PFIZER INC THIRD-QUARTER 2005 PERFORMANCE REPORT
PFIZER ACHIEVES THIRD-QUARTER REVENUE OF $12.189 BILLION,
REPORTED NET INCOME OF $1.589 BILLION, REPORTED DILUTED EPS
OF $.22, ADJUSTED INCOME* OF $3.811 BILLION,
ADJUSTED DILUTED EPS* OF $.51
---
New-Product Pipeline Continues to Advance with U.S. Launches of
Zmax, Revatio, and Lyrica; Positive Regulatory Recommendation of
Macugen in Europe; Acquisition of Vicuron Pharmaceuticals;
Receipt of FDA Approvable Letter for Dalbavancin; FDA Advisory
Panel Recommendation and Positive Opinion by European Regulators
on Exubera; U.S. and E.U. Filings of Sutent; Completion of
Phase III Clinical Program for Varenicline
---
Company Making Substantial Progress with
“Adapting to Scale” Initiative, Most Organizational Decisions
Have Already Been Announced or Will Be Announced
During Next Few Months
---
Pfizer Now Forecasts 2005 Adjusted Diluted EPS∗ of $1.92-$1.94,
2005 Reported Diluted EPS of $1.02-$1.04, Will Now Provide New
Forward-Looking Guidance Early Next Year
NEW YORK, October 20 -- Pfizer today reported financial results
for the third quarter of 2005.

Click here for the report
http://www.pfizer.se/upload/Q305%20Performance%20Release.pdf